

Appointments to the Board of Directors

[BRYN Resources](#)

Symbol

[BRYN](#)

2008-12-22 16:44 ET - News Release

TORONTO, Dec. 22 /PRNewswire-FirstCall/ - Rnet Health. Inc. is pleased to announce the following appointments to the Board:

Paul Diana, CFA, MBA, Director and C.E.O

Mr. Diana is a Senior Finance Manager with extensive experience in financial analysis, planning, forecasting, portfolio and risk management. He is currently Senior Manager, with HSBC Finance, providing planning, forecasting and loss provisions analysis. Over the past decade, he has held key positions with major Canadian financial institutions, such as Bank of Montreal where he provided profitability analysis for the development of franchise business, Global Financial Institutions.

Navin Varshney, P. Eng. - Chief Executive Officer, Director and Promoter

Current president of a private engineering/consulting company, which has been providing structural and geotechnical engineering services on residential projects for the past 17 years. Mr. Varshney obtained his Bachelor of Science degree in Engineering from Aligarh Muslim University, India in 1982 and his P. Eng. designation from the Association of Professional Engineers & Geoscientist of British Columbia.

Robert Dixon, Director

Mr. Dixon, a mining veteran with over 35 years experience, has been involved in the mining of gold, diamonds, bauxite and coal for public as well as private companies in North and South America. He is also the owner and CEO of a private exploration company which has a gold and diamond project in Guyana. This late stage project is a near term producer.

Romano Robusto, LL.B, B.C.L, BSc., Director

Mr. Romano Robusto has worked in the life sciences industry since 1988 and has held a broad range of positions including Intellectual Property, Sales, Business Development, Strategic Planning and Senior Management.

Mr. Robusto most recently worked within the life sciences division of the SGF, the economic development arm of the Quebec Government, responsible for investing development capital into companies that had achieved commercial viability. From 1988 to 1996 he held numerous positions within the Diagnostic division of Biochem Pharma, during which time the Division grew to \$150 Million in revenues and 600 employees worldwide. He holds degrees in Common and Civil law from McGill University, a BSc in Physical Therapy from McGill University and majored in Biochemistry at Concordia University. Mr Robusto presently is a director of MCN Bioproducts and Chairman of the Board and Interim CEO of Radiant Technologies Inc.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.